Abstract
Homeostasis of most tissues and organs is maintained by tissue-specific somatic or adult stem cells (SCs) and their early progenitors possessing two main properties: self-renewal and differentiation. To fulfil these two functions, they must undergo either symmetrical division for stem cell expansion, necessary after injury for example, or asymmetrical division for stem cell maintenance and progenitor production. The “cancer stem cell hypothesis” postulates that tumours arise from adult stem cells called cancer stem cells (CSCs) that possess stem cell properties. There is growing evidence that most solid tumours and haematological malignancies are driven by CSCs as a result of advances in stem cell biology and the development of animal models. This has fundamental implications for understanding the biology of cancers and also for developing new therapeutic strategies. The recent characterisation of CSC in head and neck squamous cell carcinoma (HNSCC) prompted us to re-examine the disease development and to discuss the limited effects of conventional therapies.
Keywords: Stem cell, cancer stem cell, p63, head and neck squamous cell carcinoma, oral epithelium
Current Cancer Therapy Reviews
Title: Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma
Volume: 5 Issue: 2
Author(s): Mathilde Lechevrel and Brigitte Sola
Affiliation:
Keywords: Stem cell, cancer stem cell, p63, head and neck squamous cell carcinoma, oral epithelium
Abstract: Homeostasis of most tissues and organs is maintained by tissue-specific somatic or adult stem cells (SCs) and their early progenitors possessing two main properties: self-renewal and differentiation. To fulfil these two functions, they must undergo either symmetrical division for stem cell expansion, necessary after injury for example, or asymmetrical division for stem cell maintenance and progenitor production. The “cancer stem cell hypothesis” postulates that tumours arise from adult stem cells called cancer stem cells (CSCs) that possess stem cell properties. There is growing evidence that most solid tumours and haematological malignancies are driven by CSCs as a result of advances in stem cell biology and the development of animal models. This has fundamental implications for understanding the biology of cancers and also for developing new therapeutic strategies. The recent characterisation of CSC in head and neck squamous cell carcinoma (HNSCC) prompted us to re-examine the disease development and to discuss the limited effects of conventional therapies.
Export Options
About this article
Cite this article as:
Lechevrel Mathilde and Sola Brigitte, Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma, Current Cancer Therapy Reviews 2009; 5 (2) . https://dx.doi.org/10.2174/157339409788166797
DOI https://dx.doi.org/10.2174/157339409788166797 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phenolic Compounds in Prevention and Treatment of Skin Cancers: A Review
Current Medicinal Chemistry Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Histone Modifier Differentially Regulates Gene Expression and Unravels Survival Role of MicroRNA-494 in Jurkat Leukemia
MicroRNA Actinic Keratosis: Review of the Literature and New Patents
Recent Patents on Inflammation & Allergy Drug Discovery Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Identification of Novel 5,6-Dimethoxyindan-1-one Derivatives as Antiviral Agents
Medicinal Chemistry RecQ Family Helicases in Replication Fork Remodeling and Repair: Opening New Avenues towards the Identification of Potential Targets for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry “Metabolic Reprogramming” in Ovarian Cancer Cells Resistant to Cisplatin
Current Cancer Drug Targets Neurodegeneration in the Brain Tumor Microenvironment: Glutamate in the Limelight
Current Neuropharmacology The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer
Current Pharmaceutical Design Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine MicroRNAs and Cancer: Towards a Personalized Medicine
Current Molecular Medicine Induction of Apoptosis and Sensitization of Head and Neck Squamous Carcinoma Cells to Cisplatin by Targeting Survivin Gene Expression
Current Gene Therapy The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
Clinical Cancer Drugs Molecular Imaging Aided Improvement in Drug Discovery and Development
Current Biotechnology Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Notch Signalling: A Potential Therapeutic Pathway in Oral Squamous Cell Carcinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets